StockData
Palvella Therapeutics, Inc. logo

Palvella Therapeutics, Inc. (PVLA) stock

PVLANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$146.58+2.23 (+1.54%)

Close on Nov 18, 2026Market cap $2.11BP/E –Yield –

Palvella Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Palvella Therapeutics's revenue for the twelve months ending Sep 30, 2024 was $1.35M, down 97.1% year over year. For fiscal 2023 it was $42.81M, up 65.3% from the year before. Over ten years it grew 13.2% a year on average. The highest annual figure on record is $46.28M in fiscal 2019.

Annual revenue

PeriodPeriod endValueChange
FY2023Dec 31, 2023$42.81M+65.3%
FY2022Dec 31, 2022$25.90M-17.6%
FY2021Dec 31, 2021$31.42M+7.1%
FY2020Dec 31, 2020$29.32M-36.6%
FY2019Dec 31, 2019$46.28M+59.0%
FY2018Dec 31, 2018$29.10M+15.1%
FY2017Dec 31, 2017$25.28M+333.5%
FY2016Dec 31, 2016$5.83M+98.9%
FY2015Dec 31, 2015$2.93M-45.4%
FY2014Dec 31, 2014$5.37M-56.8%
FY2013Dec 31, 2013$12.43M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2024Sep 30, 2024$0-100.0%
Q2 FY2024Jun 30, 2024$0-100.0%
Q1 FY2024Mar 31, 2024$53.00K-97.3%
Q4 FY2023Dec 31, 2023$1.30M-77.8%
Q3 FY2023Sep 30, 2023$19.52M+263.5%
Q2 FY2023Jun 30, 2023$20.06M+442.3%
Q1 FY2023Mar 31, 2023$1.94M-82.4%
Q4 FY2022Dec 31, 2022$5.85M-30.8%
Q3 FY2022Sep 30, 2022$5.37M+32.4%
Q2 FY2022Jun 30, 2022$3.70M+12.6%
Q1 FY2022Mar 31, 2022$10.99M-29.7%
Q4 FY2021Dec 31, 2021$8.44M+349.8%
Q3 FY2021Sep 30, 2021$4.06M+38.0%
Q2 FY2021Jun 30, 2021$3.29M-70.8%
Q1 FY2021Mar 31, 2021$15.63M+17.9%
Q4 FY2020Dec 31, 2020$1.88M-89.1%
Q3 FY2020Sep 30, 2020$2.94M-80.6%
Q2 FY2020Jun 30, 2020$11.25M+110.9%
Q1 FY2020Mar 31, 2020$13.26M+55.2%
Q4 FY2019Dec 31, 2019$17.27M+251.4%
Q3 FY2019Sep 30, 2019$15.13M+81.3%
Q2 FY2019Jun 30, 2019$5.33M-54.4%
Q1 FY2019Mar 31, 2019$8.55M+105.8%
Q4 FY2018Dec 31, 2018$4.91M-72.9%
Q3 FY2018Sep 30, 2018$8.35M+112.5%
Q2 FY2018Jun 30, 2018$11.69M+530.9%
Q1 FY2018Mar 31, 2018$4.15M+209.2%
Q4 FY2017Dec 31, 2017$18.15M+565.8%
Q3 FY2017Sep 30, 2017$3.93M+400.3%
Q2 FY2017Jun 30, 2017$1.85M–
Q1 FY2017Mar 31, 2017$1.34M–
Q4 FY2016Dec 31, 2016$2.73M–
Q3 FY2016Sep 30, 2016$785.01K–

More Palvella Therapeutics figures

See a number that looks wrong?